Medicine and HealthNature Communications
Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways
M. Gagne, B. J. Flynn, et al.
This groundbreaking study explores the innovative use of aerosolized RBD-62 to combat SARS-CoV-2 Delta in rhesus macaques, demonstrating its ability to suppress viral replication while preserving immune responses. Conducted by a team of expert researchers, this work offers proof-of-concept for novel therapeutics that could prevent severe illnesses from emerging variants.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
An engineered ACE2 decoy neutralizes SARS-CoV-2 Omicron BA.5 in vitro and in vivo
H. B., L. G. W., et al.
Medicine and Health
Emergence and spread of a SARS-CoV-2 lineage A variant (A.23.1) with altered spike protein in Uganda
D. L. Bugembe, M. V. T. Phan, et al.
Medicine and Health
An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters
S. Deng, Y. Liu, et al.
Medicine and Health
A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein
W. Pang, Y. Lu, et al.
